GlassScriptPhysician profile
Deborah Soong
NPI 1841796158
$2,253.44
in general payments reported to CMS, 2019-2025
14 companies · $473 in 2025
The $473 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $497 · 2023: $449 · 2024: $834 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,756.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $394.21 | 2022-2025 | Enhertu |
| Glaxosmithkline, LLC. | $357.66 | 2022-2024 | Ojjaara |
| Jazz Pharmaceuticals INC. | $295.65 | 2022-2024 | Zepzelca |
| Regeneron Healthcare Solutions, INC. | $247.34 | 2022-2023 | Libtayo |
| Janssen Biotech, INC. | $193.17 | 2025 | Rybrevant, Darzalex, Tecvayli |
| Sobi, INC | $124.99 | 2024 | |
| Amgen INC. | $123.71 | 2025 | Blincyto |
| Emd Serono, INC. | $121.84 | 2023 | Bavencio |
| Adc Therapeutics America, INC. | $111.36 | 2024 | |
| Pfizer INC. | $96.89 | 2024-2025 | |
| Gilead Sciences, INC. | $82.40 | 2024 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $49.85 | 2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $27.89 | 2025 | Enhertu |
| Genzyme Corporation | $26.48 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Soong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.